Siliphos

Siliphos

Best for

Lower liver enzyme levels

Promising early signal 80–700 mg/day 4–49 weeks 3 studies, n=205 #6 of 39 studied

  • 6 papers
  • 2 of 11 outcomes
  • 1 positive

Siliphos shows a promising early signal for lowering liver enzymes in people with nonalcoholic fatty liver disease, while broader benefits remain unproven.

What siliphos actually does

Outcome Effect Evidence Dose Time Rank
Worth watching 1
Lower liver enzyme levels Promising early signal Liver blood tests can rise when liver cells are injured or bile flow is blocked.
moderate
3 RCTs 3 papers · n=205 80–700 mg 4–49 wk #6 /39
Early research 1
Less liver fat in fatty liver Not enough research Fatty liver means extra fat has built up in the liver, which can lead to liver damage over time.
trivial
1 RCT 1 papers · n=52 420–700 mg 49 wk

Effect tiers come from native-unit MCID where available, Cohen's d otherwise.

Protocol

Dose, timing & forms

How much

The early studies behind the liver-enzyme signal used reported daily amounts spanning roughly 80 to 700 mg. That wide spread is a clue that the research has not identified one proven target dose, so do not assume that a higher amount delivers a better result.1

When and how long

The available early research does not establish a meaningful advantage for morning versus evening use. What the protocols support is regular daily use over a study period, not occasional use when you feel like your liver needs a reset.1

Forms & standardisation

Look specifically for a product labeled as a silybin-phosphatidylcholine complex, often called a phytosome, rather than assuming every milk thistle product matches Siliphos. This distinction matters because the clinical trial used the complex formulation, and one trial formulation also included vitamin E, which makes it harder to credit every observed change to silybin alone.1

In context

What this is and how it works

  • Across 3 studies (n=205), Siliphos lowered liver-enzyme measures in patients with nonalcoholic fatty liver disease.1
  • Six papers reviewed here span 11 outcomes, with liver enzymes providing the strongest signal.
  • Evidence remains early, and Siliphos has not shown a meaningful reduction in liver fat.

Siliphos is a branded complex that pairs silybin, a major active compound from milk thistle, with phosphatidylcholine. Think of phosphatidylcholine as the carrier attached to the ingredient, rather than a separate liver-support supplement.1

Silybin is paired with phosphatidylcholine so the plant compound has a better shot at getting through the gut wall, like putting a fragile package into protective shipping material before delivery.1 Early clinical work tracks changes in liver blood markers after this complex is taken regularly, but it has not yet established that the complex meaningfully changes liver fat.1

Bottom line

Siliphos is worth watching if you want an experimental milk thistle formulation with an early signal for improving liver blood markers. It is not a strong pick if your main goal is reducing liver fat, since the current evidence does not show a meaningful effect there.1 If abnormal liver tests prompted your interest, use supplement decisions alongside medical evaluation rather than as a substitute for it.

Frequently asked

Common questions

What is Siliphos?

Siliphos is a silybin and phosphatidylcholine complex. Silybin is a key compound from milk thistle, while phosphatidylcholine is included to improve how the compound travels through the digestive system and into the body.1

Does Siliphos lower liver enzymes?

Early clinical findings show a promising, moderate signal for lower ALT, AST, and GGT, which are blood markers clinicians use to track liver-cell irritation. The evidence remains limited, so it does not establish a guaranteed result for every person.1

Is Siliphos proven to reduce liver fat?

No. One early study has explored liver-fat outcomes, and the observed effect was trivial. It is too soon to view Siliphos as a reliable option for changing liver-fat levels.1

Sources

Sources

  1. 1. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial (2012)

Generated August 27, 2026